ArticleEuropean journal of clinical pharmacology2013
The intriguing future of pharmacoepidemiology.
Article in European journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review.Pharmacology research & perspectives · 2020Pooled it
- Electronic data sources for drug utilization research and healthcare decision-making in Mexico.BMC health services research · 2025Article
- Mental health services in Gauteng, South Africa: A proxy evaluation using pharmaceutical data.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2024Article
- Incidence in pharmacoepidemiology-Basic definitions and types of misclassification.Basic & clinical pharmacology & toxicology · 2022Article
- Data Sources for Drug Utilization Research in Brazil-DUR-BRA Study.Frontiers in pharmacology · 2021Article
- Use of text-mining methods to improve efficiency in the calculation of drug exposure to support pharmacoepidemiology studies.International journal of epidemiology · 2018Article
- Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specification.ClinicoEconomics and outcomes research : CEOR · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the years more and more data have become available in the constantly growing databases on prescription drugs. This has facilitated the development of pharmacoepidemiology, a dynamic research field that has undergone a more rapid development than many other research areas. There are several reasons why pharmacoepidemiology will remain recognized as one of the most dynamic and challenging research areas of clinical pharmacology. The data explosion in modern society will continue, and observational studies aimed at assessing the value of medicines will be increasingly requested by payers, professionals and patients. Future studies in pharmacoepidemiology must include specialist drugs used in the hospital setting and also be designed to address obstacles hindering the delivery of effective medicines to the patient. Pharmacoepidemiological methods may also be valuable tools to address new challenges, such as the environmental impact of medicines. A potential threat is that the increasing amounts of data available in registries may add fuel to the debate on confidentiality. The too strict application of privacy rules might hinder the further development of pharmacoepidemiology.
Indexed as
Identifiers
23640187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.